Evidence map›Paper›PMID 34211847›Full record

ArticleFrontiers in oncology2021

Prospective Assessment of Early Proton Therapy-Induced Optic Neuropathy in Patients With Intracranial, Orbital or Sinonasal Tumors: Impact of A Standardized Ophthalmological Follow Up.

Marie Lecornu, Paul Lesueur, Julia Salleron, Jacques Balosso, Dinu Stefan, William Kao, Tiphaine Plouhinec, Anthony Vela, Pauline Dutheil, Jordan Bouter and 3 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Marie LecornuRadiation Oncology Department, Centre François Baclesse, Caen, France.
Paul LesueurRadiation Oncology Department, Centre François Baclesse, Caen, France.
Julia SalleronCellule Data Biostatistique, Instistut de Cancerologie de Lorraine, Nancy, France.
Jacques BalossoRadiation Oncology Department, Centre François Baclesse, Caen, France.
Dinu StefanRadiation Oncology Department, Institut Universitaire du Cancer de Toulouse, Toulouse, France.
William KaoRadiation Oncology Department, Centre François Baclesse, Caen, France.
Tiphaine PlouhinecRadiation Oncology Department, Centre François Baclesse, Caen, France.
Anthony VelaRadiation Oncology Department, Centre François Baclesse, Caen, France.
Pauline DutheilRadiation Oncology Department, Centre François Baclesse, Caen, France.
Jordan BouterRadiation Oncology Department, Centre François Baclesse, Caen, France.
Pierre-Alban MartyOphthalmology Department, University Hospital of Caen, Caen, France.
Juliette ThariatRadiation Oncology Department, Centre François Baclesse, Caen, France.
Jean-Claude QuintynOphthalmology Department, University Hospital of Caen, Caen, France.
Centre François Baclesse · FRUniversité de Caen Normandie · FRCentre National de la Recherche Scientifique · FRInstitut de Cancérologie de Lorraine · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeProton therapy (PT) can be a good option to achieve tumor control while reducing the probability of radiation induced toxicities compared to X-ray-based radiotherapy. However, there are still uncertainties about the effects of PT on the organs in direct contact with the irradiated volume. The aim of this prospective series was to report 6-month follow-up of clinical and functional optic neuropathy rates of patients treated by proton therapy using a standardized comprehensive optic examination. METHODS AND MATERIALS: Standardized ophthalmological examinations were performed to analyze subclinical anomalies in a systematic way before treatment and 6 months after the end of proton therapy with: Automatic visual field, Visual evoked potential (VEP) and optic coherence of tomography (OCT).

resultsFrom October 2018 to July 2020 we analyzed 81 eyes. No significant differences were found in the analysis of the clinical examination of visual functions by the radiation oncologist. However, considering VEP, the impairment was statistically significant for both fibers explored at 30'angle (p:0.007) and 60'angle (p <0.001). In patients with toxicity, the distance of the target volume from the optical pathways was more important with a p-value for 30'VEP at 0.035 and for 60'VEP at 0.039.

conclusionsThese results confirm uncertainties concerning relative biological effectiveness of proton therapy, linear energy transfer appears to be more inhomogeneous especially in areas close to the target volumes. The follow-up of patients after proton therapy is not an easy process to set up but it is necessary to improve our knowledges about the biological effects of proton therapy in real life. Our study which will continue during the coming years, suggests that follow-up with in-depth examinations such as VEP as a biomarker could improve the detection of early abnormalities.

Indexed as

optic pathway toleranceoptic toxicityproton therapyradiation-induced optic neuropathyradiation neuropathy

Identifiers

PMID34211847
PMCPMC8239302
OpenAlexW3170733174

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.